DD201646A5 - Verfahren zur kaltsterilisation von blutgerinnungsfaktor viii enthaltenden praeparaten - Google Patents

Verfahren zur kaltsterilisation von blutgerinnungsfaktor viii enthaltenden praeparaten Download PDF

Info

Publication number: DD201646A5
Authority: DD; German Democratic Republic
Prior art keywords: factor viii; propiolactone; treatment; concentration; irradiation
Prior art date: 1980-09-10

Application number

DD81233131A

Other languages

German (de)

English (en)

Inventor

Ronald Kotitschke

Wolfgang Stephan

Original Assignee

Biotest Serum Institut Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-09-10

Filing date

1981-09-08

Publication date

1983-08-03

1981-09-08 Application filed by Biotest Serum Institut Gmbh filed Critical Biotest Serum Institut Gmbh

1983-08-03 Publication of DD201646A5 publication Critical patent/DD201646A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 31
238000002360 preparation method Methods 0.000 title claims abstract description 16
210000004369 blood Anatomy 0.000 title description 8
239000008280 blood Substances 0.000 title description 8
230000008569 process Effects 0.000 title description 4
108010054218 Factor VIII Proteins 0.000 claims abstract description 54
102000001690 Factor VIII Human genes 0.000 claims abstract description 54
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims abstract description 27
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 24
229960000380 propiolactone Drugs 0.000 claims abstract description 21
238000001179 sorption measurement Methods 0.000 claims abstract description 19
239000008119 colloidal silica Substances 0.000 claims abstract description 17
230000001954 sterilising effect Effects 0.000 claims abstract description 14
238000004659 sterilization and disinfection Methods 0.000 claims abstract description 13
239000002736 nonionic surfactant Substances 0.000 claims abstract description 6
239000012460 protein solution Substances 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 28
-1 sorbitan fatty acid esters Chemical class 0.000 claims description 9
239000004094 surface-active agent Substances 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
235000012239 silicon dioxide Nutrition 0.000 claims description 3
229960000301 factor viii Drugs 0.000 abstract description 49
208000006454 hepatitis Diseases 0.000 abstract description 6
239000003114 blood coagulation factor Substances 0.000 abstract description 4
230000001771 impaired effect Effects 0.000 abstract description 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
230000000694 effects Effects 0.000 description 18
210000002381 plasma Anatomy 0.000 description 16
241000700605 Viruses Species 0.000 description 13
108010049003 Fibrinogen Proteins 0.000 description 10
102000008946 Fibrinogen Human genes 0.000 description 10
229940012952 fibrinogen Drugs 0.000 description 10
230000002779 inactivation Effects 0.000 description 8
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 7
239000012141 concentrate Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
231100000283 hepatitis Toxicity 0.000 description 5
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
108010035369 Cohn fraction I Proteins 0.000 description 3
102000006395 Globulins Human genes 0.000 description 3
108010044091 Globulins Proteins 0.000 description 3
230000000603 anti-haemophilic effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000036512 infertility Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
102100026735 Coagulation factor VIII Human genes 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
229940106780 human fibrinogen Drugs 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
108010012557 prothrombin complex concentrates Proteins 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000543381 Cliftonia monophylla Species 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
241000522506 Niphargus factor Species 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241000282579 Pan Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000012503 blood component Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
229940105778 coagulation factor viii Drugs 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000000003 hoof Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003253 viricidal effect Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0094—Gaseous substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultraviolet radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DD81233131A 1980-09-10 1981-09-08 Verfahren zur kaltsterilisation von blutgerinnungsfaktor viii enthaltenden praeparaten DD201646A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3033932A DE3033932C2 (de)	1980-09-10	1980-09-10	Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten

Publications (1)

Publication Number	Publication Date
DD201646A5 true DD201646A5 (de)	1983-08-03

Family

ID=6111507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD81233131A DD201646A5 (de)	1980-09-10	1981-09-08	Verfahren zur kaltsterilisation von blutgerinnungsfaktor viii enthaltenden praeparaten

Country Status (5)

Country	Link
US (1)	US4370264A (fr)
EP (1)	EP0047462A3 (fr)
JP (1)	JPS5780323A (fr)
DD (1)	DD201646A5 (fr)
DE (1)	DE3033932C2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4481189A (en) *	1982-04-14	1984-11-06	New York Blood Center Inc.	Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) *	1982-06-08	1987-02-24	The Regents Of The University Of California	Vaccine for bluetongue disease employing platinum compounds
CA1213827A (fr) *	1983-04-29	1986-11-12	Ricardo H. Landaburu	Procede de pasteurisation de la fibronectine
US4585654A (en) *	1983-04-29	1986-04-29	Armour Pharmaceutical Co.	Process for pasteurizing fibronectin
ATE59145T1 (de) *	1983-05-02	1991-01-15	Diamond Scient Co	Photochemische entkeimungsbehandlung von vollem blut oder blutbestandteilen.
US4764369A (en) *	1983-07-14	1988-08-16	New York Blood Center Inc.	Undenatured virus-free biologically active protein derivatives
US4540573A (en) *	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
US4820805A (en) *	1983-07-14	1989-04-11	New York Blood Center, Inc.	Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
DE3330770A1 (de) *	1983-08-26	1985-03-14	Behringwerke Ag, 3550 Marburg	Verfahren zur pasteurisierung von humanplasma
US4620908A (en) *	1983-10-03	1986-11-04	Biocell Laboratories, Inc.	Method for destroying microbial contamination in protein materials
US5281579A (en) *	1984-03-23	1994-01-25	Baxter International Inc.	Purified virus-free hemoglobin solutions and method for making same
EP0179075B2 (fr) *	1984-03-23	1997-10-15	BAXTER INTERNATIONAL INC. (a Delaware corporation)	Hemoglobine a risque reduit de contamination virale et son procede de preparation
US4670394A (en) *	1984-11-16	1987-06-02	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C
US4613501A (en) *	1984-12-21	1986-09-23	New York Blood Center, Inc.	Inactivation of viruses in labile blood derivatives
DE3609431A1 (de) *	1986-03-20	1987-09-24	Biotest Pharma Gmbh	Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates
DE3612137A1 (de) *	1986-04-10	1987-10-15	Biotest Pharma Gmbh	Steriles plasmaaustauschmittel
US4841023A (en) *	1986-06-25	1989-06-20	New York Blood Center, Inc.	Inactivation of viruses in labile protein-containing compositions using fatty acids
DE3730533A1 (de) *	1987-09-11	1989-03-30	Biotest Pharma Gmbh	Verfahren zur sterilisation von plasma oder plasmafraktionen
DE3733181C1 (de) *	1987-10-01	1989-01-19	Biotest Pharma Gmbh	Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates
DE3826792C1 (fr) *	1988-08-06	1989-07-06	Biotest Pharma Gmbh, 6072 Dreieich, De
DE3914869C1 (fr) *	1989-05-05	1990-08-09	Biotest Pharma Gmbh, 6072 Dreieich, De
DE4008852A1 (de) *	1990-03-20	1991-09-26	Octapharma Ag	Verfahren zur herstellung von nicht-infektioesem blutplasma
US5418130A (en) *	1990-04-16	1995-05-23	Cryopharm Corporation	Method of inactivation of viral and bacterial blood contaminants
US5798238A (en) *	1990-04-16	1998-08-25	Baxter International Inc.	Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US6187572B1 (en)	1990-04-16	2001-02-13	Baxter International Inc.	Method of inactivation of viral and bacterial blood contaminants
US20040067157A1 (en) *	1993-07-22	2004-04-08	Clearant, Inc.	Methods for sterilizing biological materials
US5362442A (en)	1993-07-22	1994-11-08	2920913 Canada Inc.	Method for sterilizing products with gamma radiation
US5741894A (en) *	1995-09-22	1998-04-21	Baxter International, Inc.	Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
EP1154796B1 (fr) *	1999-02-22	2007-06-20	University of Connecticut	Nouvelles formulations de facteur viii sans albumine
US6565802B1 (en)	1999-06-03	2003-05-20	Baxter International Inc.	Apparatus, systems and methods for processing and treating a biological fluid with light
US20040086420A1 (en) *	2000-03-23	2004-05-06	Macphee Martin J.	Methods for sterilizing serum or plasma
US6682695B2 (en) *	2001-03-23	2004-01-27	Clearant, Inc.	Methods for sterilizing biological materials by multiple rates
US6696060B2 (en)	2001-06-14	2004-02-24	Clearant, Inc.	Methods for sterilizing preparations of monoclonal immunoglobulins
US20030031584A1 (en) *	2001-08-10	2003-02-13	Wilson Burgess	Methods for sterilizing biological materials using dipeptide stabilizers
US6946098B2 (en)	2001-08-10	2005-09-20	Clearant, Inc.	Methods for sterilizing biological materials
US7252799B2 (en) *	2001-08-31	2007-08-07	Clearant, Inc.	Methods for sterilizing preparations containing albumin
US6749851B2 (en)	2001-08-31	2004-06-15	Clearant, Inc.	Methods for sterilizing preparations of digestive enzymes
US20030095890A1 (en) *	2001-09-24	2003-05-22	Shirley Miekka	Methods for sterilizing biological materials containing non-aqueous solvents
US20110091353A1 (en) *	2001-09-24	2011-04-21	Wilson Burgess	Methods for Sterilizing Tissue
US6783968B2 (en)	2001-09-24	2004-08-31	Clearant, Inc.	Methods for sterilizing preparations of glycosidases
US20030185702A1 (en) *	2002-02-01	2003-10-02	Wilson Burgess	Methods for sterilizing tissue
US20030133829A1 (en) *	2001-12-21	2003-07-17	Baxter Healthcare Corporation	Process for inactivating pathogens in a biological material
US20030124023A1 (en) *	2001-12-21	2003-07-03	Wilson Burgess	Method of sterilizing heart valves
US20030180181A1 (en) *	2002-02-01	2003-09-25	Teri Greib	Methods for sterilizing tissue
US6908591B2 (en) *	2002-07-18	2005-06-21	Clearant, Inc.	Methods for sterilizing biological materials by irradiation over a temperature gradient
US20040013562A1 (en) *	2002-07-18	2004-01-22	Wilson Burgess	Methods for sterilizing milk.
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8703467B2 (en) *	2004-05-27	2014-04-22	Baxter International Inc.	Inactivation of a pathogen in a sample by a treatment with formalin and UV light
BRPI0921429B1 (pt)	2008-11-07	2022-07-12	Takeda Pharmaceutical Company Limited	Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3717708A (en) *	1968-10-24	1973-02-20	Cutter Lab	Blood coagulation complex
US3864081A (en) *	1973-06-12	1975-02-04	Spectroderm International Inc	Apparatus for sterilizing biologic material and the like by ultra-violet irradiation
DE2459291C3 (de) *	1974-12-14	1981-06-04	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
US4170590A (en) *	1974-12-14	1979-10-09	Biotest-Serum-Institut Gmbh	Ion exchanger treatment of citrate-stabilized plasma
US4069216A (en) *	1975-06-16	1978-01-17	Edward Shanbrom, Inc.	Simplified methods for preparation of very high purity Factor VIII concentrate
IL58541A (en) *	1978-11-01	1982-02-28	Nordisk Insulinlab	Antihemophilic factor preparation from human blood plasma and a process for producing it
DE2901822A1 (de) *	1979-01-18	1980-07-31	Biotest Serum Institut Gmbh	Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) *	1979-01-20	1980-07-31	Biotest Serum Institut Gmbh	Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4305870A (en) *	1979-01-31	1981-12-15	Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte	Intravenous plasma derivatives and their production

1980
- 1980-09-10 DE DE3033932A patent/DE3033932C2/de not_active Expired
1981
- 1981-08-31 EP EP81106790A patent/EP0047462A3/fr not_active Ceased
- 1981-09-08 US US06/300,074 patent/US4370264A/en not_active Expired - Fee Related
- 1981-09-08 DD DD81233131A patent/DD201646A5/de unknown
- 1981-09-09 JP JP56141130A patent/JPS5780323A/ja active Pending

Also Published As

Publication number	Publication date
DE3033932C2 (de)	1984-05-24
US4370264A (en)	1983-01-25
EP0047462A2 (fr)	1982-03-17
EP0047462A3 (fr)	1982-08-04
DE3033932A1 (de)	1982-03-18
JPS5780323A (en)	1982-05-19

Publication	Publication Date	Title
DE3033932C2 (de)	1984-05-24	Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
DE3382716T2 (de)	1994-03-31	Verfahren zur Wärmebehandlung von Plasma oder Plasmafraktionen und so erhaltene Zusammensetzungen.
DE3734923C1 (de)	1989-01-26	Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE3880292T2 (de)	1993-09-09	Ausscheidung von prozesschemikalien aus biologischen gemischen mit halogenierten kohlenwasserstoffen.
DE3876600T2 (de)	1993-04-15	Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
DE69333928T2 (de)	2006-08-17	Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
DE69831684T2 (de)	2006-06-22	Verfahren zur Herstellung von hochvirusfreiem Thrombin zur Bereitung von Fibrinkleber aus menschlichem Plasma-Pool
EP0882455A1 (fr)	1998-12-09	Produit sanguin dans lequel les virus ont été inactivés
DD146892A5 (de)	1981-03-11	Verfahren zur herstellung eines antihaemophiliefaktorpraeparates aus menschlichem blutplasma
DE2459291A1 (de)	1976-06-16	Verfahren zur gleichzeitigen herstellung von drei therapeutisch verwendbaren produkten aus einem ausgangsmaterial
EP0413188A2 (fr)	1991-02-20	Procédé de préparation d'immunogluboline, non-modifiée contenant des IgM et/ou des IgA, administrables par voie intraveineuse
DE2715832C3 (de)	1980-01-03	Verfahren zur Gewinnung von gereinigtem antihämophilem Globulin A (Faktor VIII)
DE69321007T2 (de)	1999-04-01	Zusammensetzung zur Stabilisierung von Blutplasma im Laufe der Pasteurisation und Pasteurisationsverfahren unter Verwendung dieser Zusammensetzung
EP0271885A2 (fr)	1988-06-22	Médicament contenant la protéine tissulaire PP4, procédé de préparation de PP4 et sa pasteurisation et l'utilisation de PP4
DE3888571T2 (de)	1994-08-11	Stabilisierung von biologischen und pharmazeutischen Produkten während der Inaktivierung von viralen und bakteriellen Keimen.
DE3330770A1 (de)	1985-03-14	Verfahren zur pasteurisierung von humanplasma
AT402789B (de)	1997-08-25	Pharmazeutische präparation auf basis von plasmaproteinen
DE1767285B2 (de)	1980-12-04	Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie
DE19600939C1 (de)	1997-08-28	Verfahren zur Trennung von IgG und IgA
EP0237981A2 (fr)	1987-09-23	Procédé de production d'une préparation stérile contenant le facteur VIII de coagulation du sang
DE19623293C2 (de)	1998-10-22	Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
DE68913212T2 (de)	1994-05-19	Ein reines faktor i-protein und verfahren zur herstellung.
DE3324289A1 (de)	1985-01-17	Verfahren zur herstellung von sterilisierten humanen blutplasmaproteinen
DE19528221C2 (de)	1998-10-22	Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
AT402892B (de)	1997-09-25	Verfahren zur herstellung eines virussicheren biologischen präparates